| Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer T Powles, BP Valderrama, S Gupta, J Bedke, E Kikuchi, ... New England Journal of Medicine 390 (10), 875-888, 2024 | 336 | 2024 |
| Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy International Prognostic Factors Study Group Journal of Clinical Oncology 28 (33), 4906-4911, 2010 | 309 | 2010 |
| Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa P Pedrazzoli, A Farris, S Del Prete, F Del Gaizo, D Ferrari, C Bianchessi, ... Journal of Clinical Oncology 26 (10), 1619-1625, 2008 | 239 | 2008 |
| Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab U De Giorgi, G Procopio, D Giannarelli, R Sabbatini, A Bearz, S Buti, ... Clinical Cancer Research 25 (13), 3839-3846, 2019 | 207 | 2019 |
| Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’trial R Labianca, A Sobrero, L Isa, E Cortesi, S Barni, D Nicolella, M Aglietta, ... Annals of oncology 22 (5), 1236-1242, 2011 | 154 | 2011 |
| LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+ P) vs chemotherapy (Chemo) in previously untreated … TB Powles, BP Valderrama, S Gupta, J Bedke, E Kikuchi, ... Annals of Oncology 34, S1340, 2023 | 146 | 2023 |
| Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor U De Giorgi, G Rosti, M Aieta, F Testore, L Burattini, G Fornarini, ... European urology 50 (5), 1032-1039, 2006 | 101 | 2006 |
| Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment … O Caffo, U De Giorgi, L Fratino, D Alesini, V Zagonel, G Facchini, ... European urology 68 (1), 147-153, 2015 | 100 | 2015 |
| CDKN2A is the main susceptibility gene in Italian pancreatic cancer families P Ghiorzo, G Fornarini, S Sciallero, L Battistuzzi, F Belli, L Bernard, ... Journal of medical genetics 49 (3), 164-170, 2012 | 91 | 2012 |
| Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme U De Giorgi, G Cartenì, D Giannarelli, U Basso, L Galli, E Cortesi, ... Bju International 123 (1), 98-105, 2019 | 87 | 2019 |
| Primary mediastinal germ cell tumors G Rosti, S Secondino, A Necchi, G Fornarini, P Pedrazzoli Seminars in oncology 46 (2), 107-111, 2019 | 81 | 2019 |
| Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) SE Rebuzzi, A Signori, GL Banna, M Maruzzo, U De Giorgi, P Pedrazzoli, ... Therapeutic advances in medical oncology 13, 17588359211019642, 2021 | 74 | 2021 |
| Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the ‘GISCAD-alternating schedule’study findings M Mandalà, S Barni, I Floriani, L Isa, G Fornarini, M Marangolo, S Mosconi, ... European Journal of Cancer 45 (1), 65-73, 2009 | 63 | 2009 |
| First-line PAzopanib in NOn–clear-cell renal cArcinoMA: The Italian retrospective multicenter PANORAMA study S Buti, M Bersanelli, F Maines, G Facchini, F Gelsomino, F Zustovich, ... Clinical genitourinary cancer 15 (4), e609-e614, 2017 | 61 | 2017 |
| First-line single-agent cetuximab in patients with advanced colorectal cancer A Pessino, S Artale, S Sciallero, A Guglielmi, G Fornarini, IC Andreotti, ... Annals of oncology 19 (4), 711-716, 2008 | 60 | 2008 |
| Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer S Bracarda, A Gernone, D Gasparro, P Marchetti, M Ronzoni, R Bortolus, ... Future Oncology 10 (6), 975-983, 2014 | 53 | 2014 |
| BRCA1 and BRCA2 mutations in central and southern Italian patients L Ottini, C D'Amico, C Noviello, S Lauro, M Lalle, G Fornarini, ... Breast Cancer Research 2, 1-8, 2000 | 52 | 2000 |
| Influenza vaccine indication during therapy with immune checkpoint inhibitors: a transversal challenge. The INVIDIa study M Bersanelli, D Giannarelli, P Castrignanò, G Fornarini, S Panni, ... Immunotherapy 10 (14), 1229-1239, 2018 | 51 | 2018 |
| Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort G Fornarini, SE Rebuzzi, GL Banna, F Calabrò, G Scandurra, U De Giorgi, ... ESMO open 6 (3), 100118, 2021 | 50 | 2021 |
| Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: The MetaPan study F Leone, S Artale, D Marino, C Cagnazzo, S Cascinu, C Pinto, G Fornarini, ... Cancer 119 (19), 3429-3435, 2013 | 49 | 2013 |
